Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

High Content Screening Analysis Platform

By Drug Discovery Trends Editor | May 8, 2009

Genedata has released Genedata Screener 7.0, the latest version of its open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS) analysis. Screener 7.0 combines an enterprise-wide assay data management platform with high-performance processing workflows and flexible analysis tools and provides access to high content screening-specific functionality.


Screener 7.0 can be integrated with any plate-based high content screening (HCS) instrument or image analysis software, including image databases via the HCS Image API. It is fully compatible with the Thermo Scientific Cellomics Store image management system and integration with additional platform technology providers will follow.


Screener 7.0 also advances support of multiplexed assay formats and technologies, such as HCS, label-free and multiplex target assays. Data from multiple read-outs can be compared and combined both visually and statistically, in scatter and distribution plots, statistical tables, and user-definable calculations across read-outs. New functionality also enables the consistent generation of hit lists from such assays, exploiting their multiple read-outs in a concise fashion, documenting the criteria applied and managing the results centrally for shared access.


Genedata 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50